Friday 16 October 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.
1.31
0.17
−11.49%
Follow AVXL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
11.60 | 20.87 | 18.24 | 15.62 |
Net Debt/EBITDA |
9.46 | 19.43 | 19.65 | (17.56) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 1.26 | 0.83 | (1.16) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.10) | (0.08) | (0.05) | (0.10) | |
Cash per Share |
1.20 | 1.48 | 1.37 | 1.28 | |
Shareholders Equity per Share |
1.11 | 1.42 | 1.31 | 1.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.11 | 1.42 | 1.31 | 1.21 | |
Free Cash Flow |
(8.60) | (7.15) | (4.44) | (9.10) | |
Working Capital |
94.87 | 126.62 | 121.71 | 112.45 | |
Net Current Asset Value |
94.87 | 126.62 | 121.71 | 112.45 | |
| Other line items | |||||
Quick Ratio |
11.56 | 20.81 | 18.18 | 15.51 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.08) | (0.05) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
1.63 | 1.70 | 0.80 | 0.91 | |
Average Payables |
6.94 | 3.60 | 4.76 | 5.20 | |
Average Assets |
119.69 | 128.52 | 122.95 | 111.29 | |
Average Common Equity |
107.57 | 118.77 | 110.73 | 101.70 |
Columns are period end dates